Teza Capital Management LLC Sarepta Therapeutics, Inc. Transaction History

Teza Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$93.7 - $141.53 $344,909 - $520,971	3,681 New	3,681 $476,000
Q3 2023 Feb 22, 2024	BUY	$102.5 - $123.59 $478,470 - $576,918	4,668 New	4,668 $565,000
Q3 2023 Nov 14, 2023	BUY	$102.5 - $123.59 $812,517 - $979,697	7,927 New	7,927 $960,000
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $153,912 - $201,630	-1,526 Reduced 29.85%	3,587 $464,000
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $120,000 - $188,995	1,585 Added 44.93%	5,113 $565,000
Q2 2022 Aug 15, 2022	BUY	$62.69 - $88.44 $221,170 - $312,016	3,528 New	3,528 $264,000
Q3 2021 Nov 10, 2021	SELL	$65.97 - $92.48 $732,530 - $1.03 Million	-11,104 Closed	0 $0
Q2 2021 Aug 06, 2021	BUY	$69.38 - $86.75 $770,395 - $963,272	11,104 New	11,104 $863,000
Q3 2020 Nov 12, 2020	SELL	$127.12 - $172.34 $1.28 Million - $1.73 Million	-10,049 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$93.0 - $171.7 $934,557 - $1.73 Million	10,049 New	10,049 $1.61 Million

559

85.5M

3.67M

1.75M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.5B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Teza Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Teza Capital Management LLC with notifications on news.